Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 65.87 Bil Enterprise Value: 59.05 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Citi BioPharma Conference Transcript

Sep 06, 2023 / 12:50PM GMT
Release Date Price: MXN620.75
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

So welcome, everyone. I'm Yigal Nochomovitz, one of the biotech analysts at Citi. My pleasure to have with me my colleague, Samantha Semenkow, recently rejoined Citi as a senior analyst. This is the rare neuro panel, and it's my pleasure to have with me two distinguished CEOs in the space. Carole Ben-Maimon, the CEO of Lamar and Emil Kakkis, the CEO of Ultragenyx. So welcome, both of you. Thank you very much for taking the time. And maybe just to start out, if you could just give a very brief 2- or 3-minute overview of some of the rare neurology programs that you're focused on. And then from there, we can move into some more thematic questions related to development of drugs for rare neurology. So Emil, you want to start?

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director

Okay. Sure. Good morning, everyone. So I'm Emil Kakkis, CEO of Ultragenyx. And we've been formed for about 13 years ago and have been building a portfolio of products in the [born] errors,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot